In this exploratory study, we demonstrated an inverse association between systemic CCL3 levels and risk of VTE in patients with glioma, and this observation was independent of important VTE predictors, such as tumor grade, and previously reported VTE-related systemic and local biomarkers in glioma, such as IDH1 mutation status and podoplanin expression on tumor cells. Here, CCL3 is linked to central nervous system cancer.